|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||108.14 - 110.43|
|52 Week Range||72.13 - 122.15|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||33.48|
|Earnings Date||Nov 24, 2020|
|Forward Dividend & Yield||2.32 (2.14%)|
|Ex-Dividend Date||Sep 24, 2020|
|1y Target Est||117.17|
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that further validate the superiority of DTM™ Spinal Cord Stimulation (SCS) in providing back pain relief, compared with conventional SCS therapy, using the Medtronic Intellis™ platform.
Feasibility Study of Medtronic Drug-Coated Balloon Technology for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb IschemiaDUBLIN, Oct. 18, 2020 /CNW/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first-ever results from the IN.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health